TLSA Projected Dividend Yield
Ord/Tiziana Life Sciences Ltd ( NASDAQ : TLSA )Tiziana Life Sciences Ltd. is a United Kingdom-based clinical-stage biotechnology company. Co. develops transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for secondary progressive multiple sclerosis, Crohn's Disease and KRAS+ NSCLC. Its pipeline candidates include Foralumab (TZLS-401), Anti IL-6R mAb (TZLS-501) and Milciclib (TZLS-201). Foralumab (TZLS-401) is a fully human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's and neurodegenerative diseases. 21 YEAR PERFORMANCE RESULTS |
TLSA Dividend History Detail TLSA Dividend News TLSA Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |